COMP <GO>
ONC vs RPRX // EV/EBITDA & P/E VALUATION
BeOne Medicines Ltd. (NASDAQ) VS. Royalty Pharma plc (Class A) (NASDAQ) • 15-METRIC TALLY: ONC 6
— RPRX 6
▲ EV/EBITDA & P/E VALUATION LEADER: RPRX
LAST: $370.33 (-0.33%) • MKT CAP: $42.25B
valuation
63.9x
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
valuation
27.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONC VS. RPRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONC | RPRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.50% | 7.00% | +3.50 | ONC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 63.9x | 27.8x | +36.10 | RPRX | /valuation <GO> |
| Free Cash Flow Yield | 2.23% | 6.29% | -4.06 | RPRX | /fcf-yield <GO> |
| Operating Margin | 8.40% | 65.60% | -57.20 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 32.40% | -27.00 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 40.20% | 5.10% | +35.10 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.68 | 2.90 | +3.78 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 68.6 | -15.00 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.94 | +0.04 | ONC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 123.6x | 45.8x | +77.80 | RPRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.25B | $37.91B | $4.34B | ONC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONC REV | RPRX REV | ONC GROSS % | RPRX GROSS % | ONC FCF | RPRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | $2.38B | 87.5% | — | $941.7M | $2.38B |
| FY 2024 | $3.81B | $2.26B | 84.4% | — | -$633.3M | $2.67B |
| FY 2023 | $2.46B | $2.35B | — | — | -$1.27B | $2.88B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONC // BETA 0.98
RPRX // BETA 0.94